Next Generation Drug Development

A Lime Pharmacuetical Inc.& Temple University Partnership

We utilize leading-edge advancements in Machine Learning and AI to discover and develop better medicines faster.

  • Decks and Patios icon

    3 projects Active in the Pipeline

    • Small Molecule GLP1 Agonists for Addiction

    • Selective PI3K Inhibitors as Safer Cancer Drugs

    • Non-insulin Diaities Drug

  • Green Building icon

    3 More Projects Under Development

    • Targets and nature of these projects are not diclosable at thistime

  • Outdoor Spaces icon

    Software Lisencing

    DeNovo Chemical owns a perpetual and irrevocable license to Lime Drug Design, A leading edge platform for AI based drug discovery.

    Click Here for Sofware Lisence Agreement

  • Custom Additions icon

    Module Structure

    • Drug Discovery handled by Phronesis AI.

    • Testing of candidates lead by Dr. Wayne Childers and Dr. Magid Abou-Gharbia at Temple University

    • Future partnering plans with Charles Rivers for In Vivo testing and beyond.

Our Team

Projects in Action

  • Selective PI3Ka Inhibitors as Safer Cancer Drugs

    Background

    o Phosphpinosityl-3-kinase (PI3K) is a Known Cancer Target

    o Most Marketed PI3K Inhibitors are Non-selective and have

    Dose-limiting Side Effects Caused by Other PI3K Subtypes

    o PI3Ka and PI3Kd Modulate the Anti-cancer Activity; PI3Kb Causes Side Effects

    o Proof of Concept: Piqray® (apelisib):

     *Novartis PI3Ka-selective Inhibitor Approved 2022 for Pediatric PI3KCA-related Overgrowth Spectrum (PROS) and HR Positive, HER2-Negative Breast Cancer (In Combo with Fulvestrant)

    • Lime Pharma Hits

    o Two Novel Hit Scaffolds with High nM to Low nM IC50’s

     Scaffold 1 is 10-Fold Selective for PI3Ka over b, g and d

     Scaffold 2 is Equipotent for PI3Ka and PI3Kd

    (i.e., 2 “Shots on Goal” for Cancer Indication)

  • Small Molecule GLP1 Agonists for Addiction

    • Background

    o G-Protein Coupled Receptor (GPCR) Best Known for its

    Effects on GI Motility (Type 2 Diabetes, Weight Loss)

    o Preclinical Data that Possibly Supports Parkinson’s and Alzheimer’s Use

    o Current Marketed Drugs are Injected Peptides (Ozympic®, Mounjaro®, Wegovy®)

    o Currently Two Small Molecule GLP1 Agonists of Interest

     1.Pfizer: Danuglipron for T2DM (Phase II, Likely NOT CNS Penetrant, Given b.i.d.)

    2. Astra-Zeneca: ECC-5004 for T2DM (Preclinical, Likely NOT CNS Penetrant)

    o Proof of Concept:

     Reports that Ozympic® Reduces Craving for Alcohol, Nicotine & Opioids

     Recent Reports of DA-CH5, a mixed GLP-1/GIP Peptide from

    ShanXi Univ. Showing Efficacy in Animal Model of Parkinson’s

    • Lime Pharma Hits

    o Two Novel Hit Scaffolds

     Both Scaffolds Possess Drug-like Properties that Suggest Good CNS Penetration

     Pharmacological Profiling in Progress

  • Non-Insulin Diabetis Drug

    More information coming soon

Our plans for the future

-Future Partnership with Charles Rivers to be finalized. Secure further investment as seen in term sheet.

- DeNovo Chem has a Mandate to engage with other Contract Research Organizations involving testing for any new projects taken on in the future (excluding the 6 projects above)

Want to invest in?

1. Current Projects

2. Future Projects

3. DeNovo Chemicals

Contact Rick Fine for Discussion - rick@phronesisai.com